Publicacións nas que colabora con José Antonio Pons Miñano (19)

2024

  1. GEMA-Na and MELD 3.0 severity scores to address sex disparities for accessing liver transplantation: a nationwide retrospective cohort study

    eClinicalMedicine, Vol. 74

2023

  1. Effectiveness and safety of once-daily tacrolimus formulations in de novo liver transplant recipients: The PRETHI study

    Clinical Transplantation, Vol. 37, Núm. 12

2022

  1. Consensus Statement on Hemostatic Management, Anticoagulation, and Antiplatelet Therapy in Liver Transplantation

    Transplantation, Vol. 106, Núm. 6, pp. 1123-1131

  2. Decreased Long-Term Severe Acute Respiratory Syndrome Coronavirus 2–Specific Humoral Immunity in Liver Transplantation Recipients 12 Months After Coronavirus Disease 2019

    Liver Transplantation, Vol. 28, Núm. 6, pp. 1039-1050

  3. Effects of everolimus plus minimized tacrolimus on kidney function in liver transplantation: REDUCE, a prospective, randomized controlled study

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 114, Núm. 6, pp. 335-342

2021

  1. Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients

    American Journal of Transplantation, Vol. 21, Núm. 8, pp. 2876-2884

  2. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients

    Journal of Hepatology, Vol. 74, Núm. 1, pp. 148-155

2018

  1. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study

    American Journal of Transplantation, Vol. 18, Núm. 10, pp. 2513-2522

  2. Influence of donor liver CYP3A4∗20 loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients

    Pharmacogenetics and Genomics, Vol. 28, Núm. 2, pp. 41-48

2017

  1. Efficacy and safety of daclatasvir-based antiviral therapy in hepatitis C virus recurrence after liver transplantation. Role of cirrhosis and genotype 3. A multicenter cohort study

    Transplant International, Vol. 30, Núm. 10, pp. 1041-1050

  2. Recommendations of everolimus use in liver transplant

    Gastroenterologia y Hepatologia

2016

  1. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma

    Hepatology, Vol. 63, Núm. 2, pp. 488-498

2015

  1. Perfil clínico y seguimiento de los pacientes con hepatitis C crónica en hospitales españoles: Estudio disHCovery

    Revista Espanola de Quimioterapia, Vol. 28, Núm. 3, pp. 145-153

  2. V Reunión de Consenso de la Sociedad Española de Trasplante Hepático sobre receptores de riesgo elevado, escenarios actuales de inmunosupresión y manejo del hepatocarcinoma en espera de trasplante

    Cirugia Espanola, Vol. 93, Núm. 10, pp. 619-637

2014

  1. "very early" intrahepatic cholangiocarcinoma in cirrhotic patients: Should liver transplantation be reconsidered in these patients?

    American Journal of Transplantation, Vol. 14, Núm. 3, pp. 660-667

  2. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: A spanish matched cohort multicenter study

    Annals of Surgery, Vol. 259, Núm. 5, pp. 944-952

2013

  1. Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in caucasian spanish liver transplant patients

    Journal of Clinical Pharmacology, Vol. 53, Núm. 11, pp. 1146-1154

2007

  1. Gastrointestinal Complications in Liver Transplant Recipients: MITOS Study

    Transplantation Proceedings, Vol. 39, Núm. 7, pp. 2311-2313

1999

  1. Late orthotopic liver retransplant: Indications and survival

    Transplantation Proceedings